282
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Prevention of episodic migraine with topiramate: a prospective 24-week, open-label, flexible-dose clinical trial with optional 24 weeks follow-up in a community setting

, , , , , , & show all
Pages 1119-1129 | Accepted 04 Feb 2010, Published online: 15 Mar 2010

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Anna Ferrari, Ilaria Tiraferri, Laura Neri & Emilio Sternieri. (2011) Clinical pharmacology of topiramate in migraine prevention. Expert Opinion on Drug Metabolism & Toxicology 7:9, pages 1169-1181.
Read now

Articles from other publishers (6)

Angelo Camporeale, David Kudrow, Ryan Sides, Shufang Wang, Annelies Van Dycke, Katherine J. Selzler & Virginia L. Stauffer. (2018) A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurology 18:1.
Crossref
Dawn C Buse, Richard B Lipton, Yngve Hallström, Uwe Reuter, Stewart J Tepper, Feng Zhang, Sandhya Sapra, Hernan Picard, Daniel D Mikol & Robert A Lenz. (2018) Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia 38:10, pages 1622-1631.
Crossref
Marco Mula. (2012) Topiramate and cognitive impairment: evidence and clinical implications. Therapeutic Advances in Drug Safety 3:6, pages 279-289.
Crossref
R. ShahienK. Beiruti. (2012) Preventive Agents for Migraine: Focus on the Antiepileptic Drugs. Journal of Central Nervous System Disease 4, pages JCNSD.S9049.
Crossref
Peer Tfelt-Hansen, Julio Pascual, Nabih Ramadan, Carl Dahlöf, Domenico D'Amico, Hans-Christopher Diener, Jakob Møller Hansen, Michel Lanteri-Minet, Elisabeth Loder, Douglas McCrory, Sandra Plancade & Todd Schwedt. (2012) Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. Cephalalgia 32:1, pages 6-38.
Crossref
Kristine J. Steffen & Ronette L. Kolotkin. (2012) A Review of the Combination of Phentermine and Topiramate Extended-Release for Weight Loss. Combination Products in Therapy 2:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.